Increased  ||| S:0 E:10 ||| JJ
IL-17A  ||| S:10 E:17 ||| NN
in  ||| S:17 E:20 ||| IN
atrial  ||| S:20 E:27 ||| JJ
fibrillation  ||| S:27 E:40 ||| JJ
correlates  ||| S:40 E:51 ||| NN
with  ||| S:51 E:56 ||| IN
neutrophil  ||| S:56 E:67 ||| VBG
to  ||| S:67 E:70 ||| TO
lymphocyte  ||| S:70 E:81 ||| VB
ratio  ||| S:81 E:87 ||| NN
Atrial  ||| S:87 E:94 ||| NNP
Fibrillation  ||| S:94 E:107 ||| NNP
( ||| S:107 E:108 ||| -LRB-
AF ||| S:108 E:110 ||| NNP
)  ||| S:110 E:112 ||| -RRB-
is  ||| S:112 E:115 ||| VBZ
the  ||| S:115 E:119 ||| DT
most  ||| S:119 E:124 ||| RBS
common  ||| S:124 E:131 ||| JJ
cardiac  ||| S:131 E:139 ||| JJ
arrhythmia  ||| S:139 E:150 ||| NN
and  ||| S:150 E:154 ||| CC
an  ||| S:154 E:157 ||| DT
independent  ||| S:157 E:169 ||| JJ
risk  ||| S:169 E:174 ||| NN
factor  ||| S:174 E:181 ||| NN
for  ||| S:181 E:185 ||| IN
stroke  ||| S:185 E:192 ||| NN
among  ||| S:192 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
elderly ||| S:202 E:209 ||| JJ
.  ||| S:209 E:211 ||| .
A  ||| S:211 E:213 ||| DT
role  ||| S:213 E:218 ||| NN
for  ||| S:218 E:222 ||| IN
inflammation  ||| S:222 E:235 ||| NN
in  ||| S:235 E:238 ||| IN
the  ||| S:238 E:242 ||| DT
atrial  ||| S:242 E:249 ||| JJ
remodeling  ||| S:249 E:260 ||| NN
as  ||| S:260 E:263 ||| IN
well  ||| S:263 E:268 ||| RB
as  ||| S:268 E:271 ||| IN
development  ||| S:271 E:283 ||| NN
and  ||| S:283 E:287 ||| CC
recurrence  ||| S:287 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
AF  ||| S:301 E:304 ||| NNP
is  ||| S:304 E:307 ||| VBZ
known ||| S:307 E:312 ||| VBN
.  ||| S:312 E:314 ||| .
To  ||| S:314 E:317 ||| TO
compare  ||| S:317 E:325 ||| VB
IL-17A  ||| S:325 E:332 ||| CD
between  ||| S:332 E:340 ||| IN
patients  ||| S:340 E:349 ||| NNS
with  ||| S:349 E:354 ||| IN
different  ||| S:354 E:364 ||| JJ
types  ||| S:364 E:370 ||| NNS
of  ||| S:370 E:373 ||| IN
AF  ||| S:373 E:376 ||| NNP
and  ||| S:376 E:380 ||| CC
healthy  ||| S:380 E:388 ||| JJ
individuals ||| S:388 E:399 ||| NNS
.  ||| S:399 E:401 ||| .
IL-17A  ||| S:401 E:408 ||| NNP
was  ||| S:408 E:412 ||| VBD
measured  ||| S:412 E:421 ||| VBN
in  ||| S:421 E:424 ||| IN
sera  ||| S:424 E:429 ||| NN
of  ||| S:429 E:432 ||| IN
112  ||| S:432 E:436 ||| CD
patients  ||| S:436 E:445 ||| NNS
and  ||| S:445 E:449 ||| CC
107  ||| S:449 E:453 ||| CD
healthy  ||| S:453 E:461 ||| JJ
age ||| S:461 E:464 ||| NN
/ ||| S:464 E:465 ||| NNP
sex-matched  ||| S:465 E:477 ||| NNP
controls  ||| S:477 E:486 ||| VBZ
using  ||| S:486 E:492 ||| VBG
ELISA  ||| S:492 E:498 ||| NNP
assay ||| S:498 E:503 ||| NN
.  ||| S:503 E:505 ||| .
In  ||| S:505 E:508 ||| IN
sera  ||| S:508 E:513 ||| NN
of  ||| S:513 E:516 ||| IN
26  ||| S:516 E:519 ||| CD
patients  ||| S:519 E:528 ||| NNS
with  ||| S:528 E:533 ||| IN
elevated  ||| S:533 E:542 ||| CD
IL-17A  ||| S:542 E:549 ||| CD
( ||| S:549 E:550 ||| -LRB-
> ||| S:550 E:551 ||| CD
1  ||| S:551 E:553 ||| CD
Pg ||| S:553 E:555 ||| CD
/ ||| S:555 E:556 ||| CD
ml ||| S:556 E:558 ||| CD
) ||| S:558 E:559 ||| -RRB-
,  ||| S:559 E:561 ||| ,
CCL5  ||| S:561 E:566 ||| NNP
and  ||| S:566 E:570 ||| CC
CCL18  ||| S:570 E:576 ||| CD
levels  ||| S:576 E:583 ||| NNS
were  ||| S:583 E:588 ||| VBD
also  ||| S:588 E:593 ||| RB
measured ||| S:593 E:601 ||| VBN
.  ||| S:601 E:603 ||| .
IL-17A  ||| S:603 E:610 ||| NNP
was  ||| S:610 E:614 ||| VBD
significantly  ||| S:614 E:628 ||| RB
increased  ||| S:628 E:638 ||| VBN
in  ||| S:638 E:641 ||| IN
patients  ||| S:641 E:650 ||| NNS
with  ||| S:650 E:655 ||| IN
AF  ||| S:655 E:658 ||| NNP
compared  ||| S:658 E:667 ||| VBN
to  ||| S:667 E:670 ||| TO
controls  ||| S:670 E:679 ||| NNS
( ||| S:679 E:680 ||| -LRB-
1.28  ||| S:680 E:685 ||| CD
±  ||| S:685 E:687 ||| CD
3.5  ||| S:687 E:691 ||| CD
vs.  ||| S:691 E:695 ||| FW
0.19  ||| S:695 E:700 ||| FW
±  ||| S:700 E:702 ||| FW
0.64  ||| S:702 E:707 ||| FW
Pg ||| S:707 E:709 ||| FW
/ ||| S:709 E:710 ||| FW
ml ||| S:710 E:712 ||| FW
,  ||| S:712 E:714 ||| ,
p=0.001 ||| S:714 E:721 ||| CD
) ||| S:721 E:722 ||| -RRB-
.  ||| S:722 E:724 ||| .
There  ||| S:724 E:730 ||| EX
was  ||| S:730 E:734 ||| VBD
no  ||| S:734 E:737 ||| DT
significant  ||| S:737 E:749 ||| JJ
difference  ||| S:749 E:760 ||| NN
in  ||| S:760 E:763 ||| IN
the  ||| S:763 E:767 ||| DT
level  ||| S:767 E:773 ||| NN
of  ||| S:773 E:776 ||| IN
IL-17A  ||| S:776 E:783 ||| CD
between  ||| S:783 E:791 ||| IN
different  ||| S:791 E:801 ||| JJ
types  ||| S:801 E:807 ||| NNS
of  ||| S:807 E:810 ||| IN
AF ||| S:810 E:812 ||| NNP
.  ||| S:812 E:814 ||| .
IL-17A  ||| S:814 E:821 ||| NNP
was  ||| S:821 E:825 ||| VBD
significantly  ||| S:825 E:839 ||| RB
higher  ||| S:839 E:846 ||| JJR
in  ||| S:846 E:849 ||| IN
patients  ||| S:849 E:858 ||| NNS
with  ||| S:858 E:863 ||| IN
a  ||| S:863 E:865 ||| DT
history  ||| S:865 E:873 ||| NN
of  ||| S:873 E:876 ||| IN
coronary  ||| S:876 E:885 ||| JJ
artery  ||| S:885 E:892 ||| NN
bypass  ||| S:892 E:899 ||| NNS
graft  ||| S:899 E:905 ||| VBP
compared  ||| S:905 E:914 ||| VBN
to  ||| S:914 E:917 ||| TO
other  ||| S:917 E:923 ||| JJ
patients  ||| S:923 E:932 ||| NNS
( ||| S:932 E:933 ||| -LRB-
p=0.01 ||| S:933 E:939 ||| NNP
) ||| S:939 E:940 ||| -RRB-
.  ||| S:940 E:942 ||| .
A  ||| S:942 E:944 ||| DT
significant  ||| S:944 E:956 ||| JJ
positive  ||| S:956 E:965 ||| JJ
correlation  ||| S:965 E:977 ||| NN
between  ||| S:977 E:985 ||| IN
IL-17A  ||| S:985 E:992 ||| NNP
and  ||| S:992 E:996 ||| CC
CCL18  ||| S:996 E:1002 ||| CD
concentration  ||| S:1002 E:1016 ||| NN
was  ||| S:1016 E:1020 ||| VBD
found  ||| S:1020 E:1026 ||| VBN
( ||| S:1026 E:1027 ||| -LRB-
p=0.001 ||| S:1027 E:1034 ||| NNP
) ||| S:1034 E:1035 ||| -RRB-
.  ||| S:1035 E:1037 ||| .
An  ||| S:1037 E:1040 ||| DT
increase  ||| S:1040 E:1049 ||| NN
in  ||| S:1049 E:1052 ||| IN
the  ||| S:1052 E:1056 ||| DT
Neutrophil ||| S:1056 E:1066 ||| NNP
/ ||| S:1066 E:1067 ||| NNP
Lymphocyte  ||| S:1067 E:1078 ||| NNP
ratio  ||| S:1078 E:1084 ||| NN
( ||| S:1084 E:1085 ||| -LRB-
NLR ||| S:1085 E:1088 ||| NNP
)  ||| S:1088 E:1090 ||| -RRB-
was  ||| S:1090 E:1094 ||| VBD
observed  ||| S:1094 E:1103 ||| VBN
in  ||| S:1103 E:1106 ||| IN
patients  ||| S:1106 E:1115 ||| NNS
with  ||| S:1115 E:1120 ||| IN
elevated  ||| S:1120 E:1129 ||| JJ
serum  ||| S:1129 E:1135 ||| NNS
IL-17A  ||| S:1135 E:1142 ||| VBP
compared  ||| S:1142 E:1151 ||| VBN
to  ||| S:1151 E:1154 ||| TO
other  ||| S:1154 E:1160 ||| JJ
patients  ||| S:1160 E:1169 ||| NNS
( ||| S:1169 E:1170 ||| -LRB-
p=0.006 ||| S:1170 E:1177 ||| NNP
) ||| S:1177 E:1178 ||| -RRB-
.  ||| S:1178 E:1180 ||| .
Male  ||| S:1180 E:1185 ||| JJ
patients  ||| S:1185 E:1194 ||| NNS
showed  ||| S:1194 E:1201 ||| VBD
higher  ||| S:1201 E:1208 ||| JJR
increase  ||| S:1208 E:1217 ||| NN
in  ||| S:1217 E:1220 ||| IN
NLR  ||| S:1220 E:1224 ||| NNP
( ||| S:1224 E:1225 ||| -LRB-
p=0.007 ||| S:1225 E:1232 ||| NNP
)  ||| S:1232 E:1234 ||| -RRB-
which  ||| S:1234 E:1240 ||| WDT
was  ||| S:1240 E:1244 ||| VBD
accompanied  ||| S:1244 E:1256 ||| VBN
by  ||| S:1256 E:1259 ||| IN
a  ||| S:1259 E:1261 ||| DT
decrease  ||| S:1261 E:1270 ||| NN
in  ||| S:1270 E:1273 ||| IN
CCL5  ||| S:1273 E:1278 ||| NNP
( ||| S:1278 E:1279 ||| -LRB-
p=0.000 ||| S:1279 E:1286 ||| NNP
)  ||| S:1286 E:1288 ||| -RRB-
and  ||| S:1288 E:1292 ||| CC
a  ||| S:1292 E:1294 ||| DT
marginal  ||| S:1294 E:1303 ||| JJ
increase  ||| S:1303 E:1312 ||| NN
in  ||| S:1312 E:1315 ||| IN
CCL18  ||| S:1315 E:1321 ||| NNP
( ||| S:1321 E:1322 ||| -LRB-
p=0.085 ||| S:1322 E:1329 ||| NNP
)  ||| S:1329 E:1331 ||| -RRB-
compared  ||| S:1331 E:1340 ||| VBN
to  ||| S:1340 E:1343 ||| TO
females ||| S:1343 E:1350 ||| NNS
.  ||| S:1350 E:1352 ||| .
There  ||| S:1352 E:1358 ||| EX
was  ||| S:1358 E:1362 ||| VBD
an  ||| S:1362 E:1365 ||| DT
increase  ||| S:1365 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
CCL5  ||| S:1377 E:1382 ||| CD
levels  ||| S:1382 E:1389 ||| NNS
in  ||| S:1389 E:1392 ||| IN
patients  ||| S:1392 E:1401 ||| NNS
receiving  ||| S:1401 E:1411 ||| VBG
Acetylsalicylic  ||| S:1411 E:1427 ||| NNP
Acid  ||| S:1427 E:1432 ||| NNP
( ||| S:1432 E:1433 ||| -LRB-
ASA ||| S:1433 E:1436 ||| NNP
)  ||| S:1436 E:1438 ||| -RRB-
therapy  ||| S:1438 E:1446 ||| NN
( ||| S:1446 E:1447 ||| -LRB-
p=0.046 ||| S:1447 E:1454 ||| NNP
) ||| S:1454 E:1455 ||| -RRB-
.  ||| S:1455 E:1457 ||| .
The  ||| S:1457 E:1461 ||| DT
increase  ||| S:1461 E:1470 ||| NN
in  ||| S:1470 E:1473 ||| IN
IL-17A  ||| S:1473 E:1480 ||| CD
levels  ||| S:1480 E:1487 ||| NNS
is  ||| S:1487 E:1490 ||| VBZ
related  ||| S:1490 E:1498 ||| VBN
to  ||| S:1498 E:1501 ||| TO
the  ||| S:1501 E:1505 ||| DT
AF  ||| S:1505 E:1508 ||| NNP
pathology  ||| S:1508 E:1518 ||| VBD
mediated  ||| S:1518 E:1527 ||| VBN
by  ||| S:1527 E:1530 ||| IN
neutrophils  ||| S:1530 E:1542 ||| NN
and  ||| S:1542 E:1546 ||| CC
monocytes ||| S:1546 E:1555 ||| NN
.  ||| S:1555 E:1557 ||| .
The  ||| S:1557 E:1561 ||| DT
current  ||| S:1561 E:1569 ||| JJ
study  ||| S:1569 E:1575 ||| NN
signifies  ||| S:1575 E:1585 ||| VBD
the  ||| S:1585 E:1589 ||| DT
role  ||| S:1589 E:1594 ||| NN
of  ||| S:1594 E:1597 ||| IN
immune  ||| S:1597 E:1604 ||| JJ
cells  ||| S:1604 E:1610 ||| NNS
and  ||| S:1610 E:1614 ||| CC
cytokines  ||| S:1614 E:1624 ||| NN
in  ||| S:1624 E:1627 ||| IN
the  ||| S:1627 E:1631 ||| DT
pathology  ||| S:1631 E:1641 ||| NN
of  ||| S:1641 E:1644 ||| IN
AF ||| S:1644 E:1646 ||| NNP
.  ||| S:1646 E:1648 ||| .
